Neoadjuvant checkpoint blockade achieves deep or complete pathologic responses in patients with mismatch-repair-deficient and mismatch-repair-proficient early colon cancer.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
JAK/STAT3 represents a therapeutic target for colorectal cancer patients with stromal-rich tumors
Journal of Experimental & Clinical Cancer Research Open Access 01 March 2024
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Le, D. T. et al. N. Engl. J. Med. 372, 2509–2520 (2015).
Chalabi, M. et al. Nat. Med. https://doi.org/10.1038/s41591-020-0805-8 (2020).
Wei, S. C., Duffy, C. R. & Allison, J. P. Cancer Discov. 8, 1069–1086 (2018).
Tumeh, P. C. et al. Nature 515, 568–571 (2014).
Thommen, D. S. et al. Nat. Med. 24, 994–1004 (2018).
Fairfax, B. P. et al. Nat. Med. 26, 193–199 (2020).
Yost, K. E. et al. Nat. Med. 25, 1251–1259 (2019).
Siddiqui, I. et al. Immunity 50, 195–211.e10 (2019).
Łuksza, M. et al. Nature 551, 517–520 (2017).
Liu, J. et al. Cancer Discov. 6, 1382–1399 (2016).
Pai, C. S. et al. Immunity 50, 477–492.e8 (2019).
Angelova, M. et al. Cell 175, 751–765.e16 (2018).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
G.C. has received grants or research support from or is co-investigator in clinical trials by BMS, Celgene, Boehringer Ingelheim, Roche, Iovance and Kite, and has received honoraria for consultations or presentations by Roche, Genentech, BMS, AstraZeneca, Sanofi-Aventis, Nextcure and GeneosTx.
Rights and permissions
About this article
Cite this article
Coukos, G. Neoadjuvant immune-checkpoint blockade in resectable colon cancer. Nat Med 26, 473–474 (2020). https://doi.org/10.1038/s41591-020-0826-3
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41591-020-0826-3
This article is cited by
-
JAK/STAT3 represents a therapeutic target for colorectal cancer patients with stromal-rich tumors
Journal of Experimental & Clinical Cancer Research (2024)
-
Efficacy of an ALDH peptide-based dendritic cell vaccine targeting cancer stem cells
Cancer Immunology, Immunotherapy (2022)
-
Tumorvakzinierung –Strategien und Timing
Der Gastroenterologe (2021)
-
Tumorvakzinierung –Strategien und Timing
Der Internist (2021)